High Growth Tech Stocks In Australia October 2024

In This Article:

The Australian market has shown impressive momentum, climbing 1.1% in the last week and up 17% over the past year, with earnings forecasted to grow by 12% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that not only align with current market trends but also demonstrate strong potential for sustainable earnings growth.

Top 10 High Growth Tech Companies In Australia

Name

Revenue Growth

Earnings Growth

Growth Rating

Clinuvel Pharmaceuticals

22.32%

27.42%

★★★★★★

Pureprofile

14.94%

80.73%

★★★★★☆

Adherium

86.80%

73.66%

★★★★★★

ImExHS

20.47%

111.20%

★★★★★★

Telix Pharmaceuticals

20.19%

38.31%

★★★★★★

AVA Risk Group

32.56%

118.83%

★★★★★★

Careteq

37.17%

126.21%

★★★★★☆

Pointerra

56.62%

126.45%

★★★★★★

Wrkr

36.31%

100.29%

★★★★★★

Adveritas

57.98%

144.21%

★★★★★★

Click here to see the full list of 62 stocks from our ASX High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Pro Medicus

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system services to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe, with a market cap of A$19.42 billion.

Operations: Pro Medicus generates revenue primarily through the production of integrated software applications for the healthcare industry, amounting to A$161.50 million. The company operates across key markets including Australia, North America, and Europe.

Pro Medicus, an Australian tech firm specializing in healthcare imaging software, has demonstrated robust financial health with a notable 36.5% earnings growth over the past year, outpacing the industry average of 15.4%. This growth trajectory is complemented by a forecasted annual revenue increase of 17%, which although not exceeding the high-growth threshold of 20%, still surpasses the broader Australian market's expectation of 5.5%. Additionally, R&D investments remain a pivotal focus for Pro Medicus as evidenced by their consistent allocation towards innovation to maintain competitive edge and drive future growth. Recent financial disclosures reveal that Pro Medicus reported a significant jump in net income to AUD 82.79 million from AUD 60.65 million year-over-year and an increase in dividends by 33.3%, signaling strong profitability and shareholder confidence. These figures underscore the company’s ability to leverage its technical expertise and market position to generate substantial economic returns while continuing to innovate within its sector.